close
MENU
Hot Topic Hawke’s Bay
Hot Topic Hawke’s Bay
Investment
4 mins to read

‘Worst-case scenario this is a bump in the road’: Pacific Edge

Cancer diagnostics company’s share price plummets after trading halt lifted.

Two-thirds of Pacific Edge’s US commercial test by volume were for CMS patients in the 2022 financial year.

Shares in dual-listed diagnostics company Pacific Edge have plummeted after the lifting of a trading halt imposed last Friday while the company sought advice on proposed funding reimbursement changes in the US.

The share price has dropped 41% to 46c so far in trading today, after earlier hitting a

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Fiona Rotherham Mon, 01 Aug 2022
Contact the Writer: fiona@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
‘Worst-case scenario this is a bump in the road’: Pacific Edge
Investment,
95076
true